THERAPY-RELATED MYELODYSPLASTIC SYNDROME
Clinical trials for THERAPY-RELATED MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new THERAPY-RELATED MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for THERAPY-RELATED MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New stem cell therapy aims to tame transplant complications in blood cancer patients
Disease control OngoingThis study tests a new treatment called Orca-T for people with advanced blood cancers like leukemia. Orca-T is a specially prepared stem cell transplant designed to reduce serious side effects, such as graft-versus-host disease, while still fighting the cancer. About 187 particip…
Matched conditions: THERAPY-RELATED MYELODYSPLASTIC SYNDROME
Phase: PHASE3 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated May 01, 2026 15:39 UTC
-
New chemo cocktail before transplant may stop leukemia relapse
Disease control OngoingThis study tests whether giving two chemotherapy drugs (clofarabine and melphalan) before a donor stem cell transplant can prevent leukemia from returning in patients whose cancer is in remission. The approach aims to kill any remaining cancer cells and help the donor cells take …
Matched conditions: THERAPY-RELATED MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 01, 2026 15:39 UTC
-
New drug combo shows promise for Tough-to-Treat blood cancers
Disease control OngoingThis study tests a combination of two drugs, venetoclax and azacitidine, in about 34 people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) that has returned or not responded to prior treatment. The goal is to find the best dose and see how…
Matched conditions: THERAPY-RELATED MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
New combo aims to beat tough blood cancer in 33 patients
Disease control OngoingThis study tests whether combining venetoclax and azacitidine can help people with a type of blood cancer called therapy-related myelodysplastic syndrome (t-MDS), which develops after prior cancer treatment. About 33 adults with intermediate to very high risk disease will receive…
Matched conditions: THERAPY-RELATED MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: Uma Borate • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC